Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
BeyondSpring Inc
BYSI | US
1.48
USD0.03
2.07%
BYSI | US
About BeyondSpring Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
31/03/2024
As of date
09/03/2026
Close
1.48
Open
1.47
High
1.55
Low
1.36
BeyondSpring Inc. a clinical stage biopharmaceutical company together with its subsidiaries focuses on the development of cancer therapies. The company's lead asset is the Plinabulin a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents including nivolumab a PD-1 antibody for the treatment of non-small cell lung cancer; ipilimumab a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York New York.
View LessBYSI | US
Risk
69.3
Sharpe
-0.17
Luna's Score
55/100
Recommendation
Hold
Luna says (BYSI | US)
What's Working
Strength based on increasing price with high volume
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Strong Revenue Growth (> 10%)
What's not Working
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
78.3%1 month
69.3%3 months
87.0%6 months
87.5%Returns
Fundamental Ratios
PE
-
Fwd. PE
10.54
Price to book
5.38
Debt to equity
-0.15
Debt to assets
0.16
Ent. to EBITDA
0.05
Ent. to rev.
45.65
PEG
-
Other Fundamentals
EBITDA
-16.71M
MarketCap
59.64M
MarketCap(USD)
59.64M
Div. yield
-
Op. margin
-742.20
Erngs. growth
-
Rev. growth
14.30
Ret. on equity
-310.48
Short ratio
79.33
Short perc.
8.74
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.35
Range1M
0.35
Range3M
1.23
Volumes: Market Activity
Rel. volume
1.13
Price X volume
39.13K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.05 | 0.53 | Cheaper |
| Ent. to Revenue | 45.65 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 5.38 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 86.95 | 72.80 | Par |
| Debt to Equity | -0.15 | -1.23 | Expensive |
| Debt to Assets | 0.16 | 0.25 | Cheaper |
| Market Cap | 59.64M | 3.66B | Emerging |
